GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (FRA:E8LA) » Definitions » EV-to-Revenue

Geovax Labs (FRA:E8LA) EV-to-Revenue : (As of May. 13, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Geovax Labs EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Geovax Labs's enterprise value is €-2.65 Mil. Geovax Labs's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil. Therefore, Geovax Labs's EV-to-Revenue for today is .

The historical rank and industry rank for Geovax Labs's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Geovax Labs was 5766296.05. The lowest was -306.34. And the median was 393599.45.

FRA:E8LA's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.96
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-13), Geovax Labs's stock price is €0.1999. Geovax Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00. Therefore, Geovax Labs's PS Ratio for today is .


Geovax Labs EV-to-Revenue Historical Data

The historical data trend for Geovax Labs's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs EV-to-Revenue Chart

Geovax Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 1.83 30.25 -134.35 -

Geovax Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -134.35 - - - -

Competitive Comparison of Geovax Labs's EV-to-Revenue

For the Biotechnology subindustry, Geovax Labs's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Geovax Labs's EV-to-Revenue falls into.



Geovax Labs EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Geovax Labs's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-2.645/0
=

Geovax Labs's current Enterprise Value is €-2.65 Mil.
Geovax Labs's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geovax Labs  (FRA:E8LA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Geovax Labs's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.1999/0
=

Geovax Labs's share price for today is €0.1999.
Geovax Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Geovax Labs EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Geovax Labs's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Geovax Labs (FRA:E8LA) Business Description

Traded in Other Exchanges
Address
1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Geovax Labs (FRA:E8LA) Headlines

No Headlines